Mohamed A Fayed MD FCCP
Critical Care Medicine, Pleural Disease, Thoracic Oncology
Pulmonary Critical Care Faculty, UCSF Fresno
Join to View Full Profile
2335 E Kashian LnSte 280Fresno, CA 93701
Phone+1 559-256-5130
Fax+1 559-485-4504
Dr. Fayed is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Mohamed Fayed, MD, is a Pulmonologist based in Fresno, CA. He specializes in Pulmonology with subspecialties in Critical Care Medicine, Pleural Disease, and Thoracic Oncology. He obtained his medical degree from Cairo University School of Medicine and pursued his residency in Internal Medicine at Wright State University, where he later served as chief resident. Dr. Fayed also completed a fellowship in Pulmonary Disease and Critical Care Medicine at the University of California (San Francisco)/Fresno. He has been an Associate Clinical Professor at University Faculty Associates since 2017. His clinical experience includes bronchoscopy, thoracostomy, bronchiectasis, coccidioidomycosis, and mycobacterial infections. Dr. Fayed has contributed to numerous publications and has been involved in several clinical trials related to COVID-19, Mycobacterium Avium Complex, and Pulmonary Coccidioidomycosis.
Education & Training
University of California (San Francisco)/FresnoFellowship, Pulmonary Disease and Critical Care Medicine, 2014 - 2017
Wright State UniversityChief Residency, Internal Medicine, 2012 - 2013- Wright State UniversityResidency, Internal Medicine, 2009 - 2012
Cairo University School of MedicineClass of 2007
Certifications & Licensure
OH State Medical License 2009 - 2027
CA State Medical License 2014 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Clinical Trials
- ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19 Start of enrollment: 2021 Aug 03
- ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19 Start of enrollment: 2020 Oct 23
- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC Vs. Placebo + SOC in Adult Hospitalized Patients with COVID-19 Start of enrollment: 2020 Nov 25
- Join now to see all
Publications & Presentations
PubMed
- Overview of the Current Challenges in Pulmonary Coccidioidomycosis.Mohamed A Fayed, Timothy M Evans, Eyad Almasri, Kathryn L Bilello, Robert Libke
Journal of Fungi. 2024-10-18 - 5 citationsIntravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial.Samuel M Brown, Christina E Barkauskas, Birgit Grund, Shweta Sharma, Andrew N Phillips
The Lancet. Respiratory Medicine. 2023-09-01 - 2 citationsDifferentiating Lung Nodules Due tofrom Those Due to Lung Cancer Based on Radiographic Appearance.Michael W Peterson, Ratnali Jain, Kurt Hildebrandt, William Keith Carson, Mohamed A Fayed
Journal of Fungi. 2023-06-01
Press Mentions
Health Officials Express Growing Concern over Delta Variant as It Spreads in the Central ValleyJuly 3rd, 2021- California Sets Records for Cases, Deaths as Virus SurgesDecember 16th, 2020
Professional Memberships
- Member
- Member
- Member
- Extracorporeal life support organizationMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
